l-leucovorin

DRUG8 trials

Conditions

Biliary Tract CancerColorectal CancerElderly Metastatic Colorectal Cancer PatientsGastric CancerGastroesophageal Junction CancerHER2-positive Colon CancerMetastatic Colorectal CancerPancreatic Ductal Adenocarcinoma

Phase 2

Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer

TerminatedNCT00209703

Hokkaido Gastrointestinal Cancer Study GroupColorectal Cancer

Start: 2005-01-31End: 2007-06-30Target: 30Updated: 2006-04-21

Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients

NCT02904031

Gruppo Oncologico del Nord-OvestElderly Metastatic Colorectal Cancer Patients

Start: 2016-07-31End: 2020-10-31Target: 180Updated: 2020-05-12

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

CompletedNCT03721653

Gruppo Oncologico del Nord-OvestMetastatic Colorectal Cancer

Start: 2018-11-30End: 2023-08-31Updated: 2023-10-12

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

CompletedNCT04513951

Gruppo Oncologico del Nord-OvestMetastatic Colorectal Cancer

Start: 2020-04-01End: 2024-12-31Updated: 2025-01-09

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

SuspendedNCT05062889

Gruppo Oncologico del Nord-OvestHER2-positive Colon Cancer, RAS Wild-type Colon Cancer, Stage II Colon Cancer +1

Start: 2023-05-17End: 2029-12-01Target: 477Updated: 2026-02-03

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

RecruitingNCT06219941

AstraZenecaBiliary Tract Cancer, Gastric Cancer, Gastroesophageal Junction Cancer +1

Start: 2023-12-13End: 2027-09-30Target: 224Updated: 2026-02-12

Phase 3

Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

CompletedNCT00005586

Institute of Cancer Research, United KingdomColorectal Cancer

Start: 1997-10-31Target: 2500Updated: 2013-12-18

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

CompletedNCT03231722

Gruppo Oncologico del Nord-OvestMetastatic Colorectal Cancer

Start: 2017-09-13End: 2022-06-24Updated: 2023-01-05

Journal of Clinical Oncology2025-05-283 citations

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial

BMC Cancer2025-04-085 citations

CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.

Journal of Clinical Oncology2024-06-016 citations

Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.

Journal of Clinical Oncology2024-06-012 citations

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Journal of Clinical Oncology2023-08-0329 citations

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.

Journal of Clinical Oncology2023-06-0115 citations

Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.

Journal of Clinical Oncology2023-06-019 citations

Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.

Journal of Clinical Oncology2023-06-012 citations

Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2023-06-01

Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial).

2023-02-036 citations

Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

Journal of Clinical Oncology2022-06-0810 citations

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Journal of Clinical Oncology2022-06-0670 citations

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.

2022-05-27186 citations

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.

2020-07-2258 citations

First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

Journal of Clinical Oncology2020-05-2031 citations

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

2018-01-2515 citations

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

ESMO Open2018-01-0123 citations

l-leucovorin

Sponsors

Conditions

Phase 2

Phase 3

Related Papers